The document contains the transcript of an Investors' Conference Call held on November 4, 2026, to discuss the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026 (Q2 FY27).
The conference call was hosted by IIFL Capital Services Limited, with management participation from Vikram Vuppala (Chairman and Managing Director), Kamal Shah (Co-Founder), Rohit Singh (Group Chief Executive Officer), and Prashant Goenka (Group Chief Financial Officer).
The stated purpose of the call was to discuss Q2 FY27 financial results and provide business updates, including international expansion, clinical initiatives, and growth strategy.
The meeting was scheduled after the earnings announcement, as evidenced by the reference to previous letters dated October 21, 2026, and November 4, 2026.
The transcript was uploaded to the company's website at www.nephroplus.com as part of regulatory compliance with SEBI Listing Regulations.
Financial highlights disclosed include:
Q2 FY27 revenue: INR303 crores (up 23.5% YoY)
H1 FY27 revenue: INR585 crores (up 24% YoY)
Adjusted EBITDA for H1: INR135 crores (23% margin)
Adjusted PAT for H1: INR76.1 crores (up 34.7%)
Guest count: 38,814 (up 10% YoY)
Treatments grew 12% in Q2
Revenue per treatment: INR2,785 (up 9.7%)
Network: 570 clinics across six countries (500 in India, 70 international)
Cash position: INR507 crores
Capex deployment: INR102 crores in H1 FY27
Strategic updates included:
Entry into Kazakhstan through acquisition of two clinics in Almaty
Qualification for Saudi Arabia's Ministry of Health tender (one of 12 qualified bidders)
Launch of NephroPlus International Dialysis Academy (NIDA) for nurse training
Operational clinic in Riyadh, Saudi Arabia, with home dialysis services
Medium-term revenue growth guidance reiterated at 15-20% over 3-4 years
The company clarified that pharmacy products account for less than 1% of revenue and would not be significantly impacted by potential margin capping regulations.
Additional Notes Section
The document is an attachment to a regulatory filing submitted to BSE and NSE, referencing Regulation 30 and 46(2) of SEBI Listing Regulations.
The transcript includes a full Q&A session with analysts from various institutions (Helios Capital, HUF Capital, AB Capital, TCG AMC, Ambit Capital, IIFL Capital, Choice Institutional Equities, ICICI Securities, Avener Capital, Sameeksha Capital, Prescient Capital).
The transcript was edited for factual errors, with audio recordings uploaded to stock exchanges on November 4, 2026, prevailing in case of discrepancy.
